OncoMatch

OncoMatch/Clinical Trials/NCT04974866

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Is NCT04974866 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies EGFR-TK Inhibitor for carcinoma, adenoid cystic.

Phase 2RecruitingQingdao Central HospitalNCT04974866Data as of Jun 2026Location: China

Treatment: EGFR-TK InhibitorThere is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma. This is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

EGFR-TK Inhibitor

Cancer type

Head and Neck Squamous Cell Carcinoma

Performance status

ECOG 0–3(Limited self-care)

Demographics

Ages ≤ 90

Prior therapy

Min 1 prior line

Must have received: chemotherapy

previously treated with chemotherapy or local treatment (e,g transarterial chemoembolization)

Cannot have received: chemotherapy

Exception: last treatment was at least 4 weeks prior to baseline assessment

Prior chemotherapy ... within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)

Cannot have received: radiation therapy

Exception: palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)

Prior ... radiation therapy ... within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)

Cannot have received: surgery

Prior ... surgery within 4 weeks prior to study entry

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04974866 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior chemotherapy, radiation therapy, surgery disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 90 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify